Clinical Trials
250 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
EGRET
AstraZeneca
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Montefiore Medical Center
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics, Inc
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
MTAPESTRY 103
Amgen
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Aptamer Sciences, Inc.
FLAGSHP-1
Erasca, Inc.
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
PALANGI3
Centre Oscar Lambret
Study of E7386 in Participants With Selected Advanced Neoplasms
Eisai Inc.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Cartography Biosciences
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex, Inc.
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
ACT
AgonOx, Inc.
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
GlaxoSmithKline
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Bristol-Myers Squibb
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
SHIELD-1
Turning Point Therapeutics, Inc.
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
HUYABIO International, LLC.
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
HUYABIO International, LLC.
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
National Institutes of Health Clinical Center (CC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Chiome Bioscience Inc.
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Sanofi
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.